Topic
Topic
Palvella Therapeutics presented clinical and claims data at a dermatology conference, pairing trial results with real-world analysis in a move aimed at adoption and reimbursement conversations.
A newly published consensus standardizes definitions of remission and disease activity in atopic dermatitis, aligning trial endpo…
Bambusa Therapeutics has filed for an IPO to fund clinical trials of its eczema drug candidates, joining a crowded atopic dermati…
Bambusa Therapeutics is preparing an IPO to fund clinical trials of its eczema drug, Briefs Finance reports. Here's what dermatol…
REZOLVE-AA topline data show rezpegaldesleukin produces durable hair regrowth in alopecia areata, per Dermatology Times — a susta…
Icotrokinra sustained skin clearance at high-impact psoriasis sites through 2 years, per Dermatology Times. The milestone extends…
Pfizer's experimental atopic dermatitis candidate produced what the company called a "promising win" in a finance.yahoo.com syndi…
Pfizer has detailed Phase II data for its investigational atopic dermatitis candidate, setting up a direct mid-stage challenge to…
Rezpegaldesleukin delivered durable hair regrowth in the REZOLVE-AA alopecia areata trial, strengthening the case for selective I…
A cross-sectional analysis published October 8, 2026 in JAAD audits pediatric enrollment and demographic reporting across alopeci…